Last updated: June 2, 2026
Suppliers for BROMSITE (bromsiterene) APIs, key intermediates, and finished-dose manufacturers
BROMSITE is a branded pharmaceutical product sold under the active ingredient bromsiterene. No reliable supplier, API source, or finished-dose manufacturer dataset is available in the provided inputs, so a complete and accurate supplier map cannot be produced.
Which companies supply the bromsiterene API for BROMSITE?
No supplier list can be generated from the information provided.
What’s typically listed on documents that identify bromsiterene API suppliers?
- FDA Drug Master Files (DMFs) tied to the active ingredient
- Orange Book “Applicant/Manufacturer” entries for finished product
- Public labels and packaging that disclose manufacturer of record
- Patent filings that identify process chemistry makers and contract manufacturers (CMOs)
What finished-dose manufacturers make BROMSITE tablets/capsules/solution?
No finished-dose manufacturer can be identified from the information provided.
How to distinguish API vs finished-dose supply in BROMSITE
A supplier assessment requires separate sourcing fields:
- API manufacturer (DMF holder or API label claim)
- Finished-dose manufacturer (site that releases commercial product)
- Packager/labeler (often different from manufacturing site)
Do any contract manufacturers (CMOs) produce BROMSITE under toll manufacturing?
No CMO or toll-manufacturing supplier can be identified from the information provided.
Which records usually expose CMO involvement
- Facility registration in FDA’s SPL/PLR systems
- Inspection observations and import records tied to site names
- Label manufacturing statements naming the actual manufacturer
How can supplier sourcing be verified for BROMSITE in FDA and patent records?
No verification results can be generated from the information provided.
Orange Book and DMF cross-check workflow
- Match BROMSITE to Orange Book active ingredient records
- Pull Applicant/manufacturer site names from Orange Book
- Cross-check those site names to DMF holders and facility registrations
What patents or manufacturing-method claims affect who can supply bromsiterene?
No patent estate or manufacturing-method supplier constraints can be extracted from the information provided.
Why supplier mapping depends on patenting
- Process patents can block certain synthesis routes even when API characterization is similar
- Formulation patents can restrict finished-dose manufacturing without licensing
What generic or competitor suppliers might be able to produce bromsiterene for sale in the same market?
No competitor supplier set can be identified from the information provided.
Commercial impact: what does supplier concentration imply for BROMSITE availability and pricing?
No supplier concentration metrics can be calculated from the information provided.
Key Takeaways
- BROMSITE supply-chain mapping for bromsiterene (API), key intermediates, and finished-dose manufacturing cannot be completed from the provided inputs.
- Producing an accurate supplier list requires Orange Book product records, DMF linkages, and label manufacturing statements, none of which are included here.
FAQs
-
Where do I find the API manufacturer for a branded drug like BROMSITE?
Orange Book and FDA label manufacturing statements typically identify the manufacturer of record, while DMFs can identify the API source.
-
Do Orange Book listings always reveal the actual API site?
Not always; listings often show applicant/manufacturer but may not expose every upstream API site without DMF linkage.
-
How do you confirm a supplier before contracting for bromsiterene supply?
Confirm via label manufacturing statements, DMF association to the active ingredient, and facility registration details tied to production.
-
What documents identify CMO/toll manufacturing of finished-dose drugs?
Label “Manufactured for/By” statements, facility registrations, and sometimes patent or quality agreements.
-
Can patent barriers stop an API supplier even if DMF access exists?
Yes; process, intermediate, and formulation patents can require licensing or alternative routes to commercialize.
References
No sources were provided or can be cited from the supplied information.
